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Summary
Objectives: This paper draws attention to: i) key considerations 
for evaluating artificial intelligence (AI) enabled clinical decision 
support; and ii) challenges and practical implications of AI 
design, development, selection, use, and ongoing surveillance.
Method: A narrative review of existing research and evaluation 
approaches along with expert perspectives drawn from the Inter-
national Medical Informatics Association (IMIA) Working Group on 
Technology Assessment and Quality Development in Health Infor-
matics and the European Federation for Medical Informatics (EFMI) 
Working Group for Assessment of Health Information Systems.
Results: There is a rich history and tradition of evaluating AI 
in healthcare. While evaluators can learn from past efforts, 
and build on best practice evaluation frameworks and meth-
odologies, questions remain about how to evaluate the safety 
and effectiveness of AI that dynamically harness vast amounts 
of genomic, biomarker, phenotype, electronic record, and care 
delivery data from across health systems. This paper first provides 
1   Introduction
Artificial intelligence (AI) promises to trans-
form clinical decision-making processes as it 
has the potential to harness the vast amounts of 
genomic, biomarker, and phenotype data that 
is being generated across the health system 
including from health records and delivery 
systems, to improve the safety and quality of 
care decisions [1]. Today AI has been incor-
porated successfully into decision support 
systems (DSSs) for diagnosis in data-intensive 
specialties like radiology, pathology, and oph-
thalmology [2]. Future systems are expected 
to be increasingly more autonomous, going 
beyond making recommendations about 
possible clinical actions to autonomously per-
forming certain tasks such as triaging patients 
and screening referrals [3, 4]. 
a historical perspective about the evaluation of AI in healthcare. 
It then examines key challenges of evaluating AI-enabled clinical 
decision support during design, development, selection, use, 
and ongoing surveillance. Practical aspects of evaluating AI in 
healthcare, including approaches to evaluation and indicators to 
monitor AI are also discussed.
Conclusion: Commitment to rigorous initial and ongoing evalu-
ation will be critical to ensuring the safe and effective integration 
of AI in complex sociotechnical settings. Specific enhancements 
that are required for the new generation of AI-enabled clinical 
decision support will emerge through practical application. 
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In this paper, we focus on the present 
role of AI in supporting clinical decisions. 
Evaluation of these machine-learning-
based systems has tended to focus on 
examining the performance of algorithms 
in laboratory settings. There are a few 
observational studies which have tested 
systems in clinical settings providing a 
safe environment while patients continue 
to receive standard care [5]. However, 
little is known about the effects of AI on 
care delivery and patient outcomes which 
need to be carefully considered to ensure 
that it is appropriately applied. Like any 
technology, AI will also come with its 
unintended effects that may disrupt care 
delivery and pose risks to patients [6]. It 
is clear that the many benefits of AI cannot 
be realized safely unless AI is responsibly 
and effectively integrated into clinical 
decision-making and care delivery pro-
cesses, and risks are effectively identified 
and mitigated. 
While we have witnessed the beginnings 
of mainstream adoption of AI in only the 
last five years or so, academic researchers 
within the informatics community have 
studied AI for almost half a century [7-9]. 
However, an enhanced risk is now pre-
sented by a shift in the environment from 
draw-down of innovation based on positive 
evidence to political and commercial pres-
sures for speedy adoption based on promise, 
with the call for evidence being presented 
as self-interested commitment to the status 
quo [10]. Clearly this disregard of evidence 
puts patients at risk.
The objective of this paper is to draw 
attention to key considerations for evaluat-
ing AI in clinical decision support; and to 
examine challenges and practical implica-
tions of AI design, development, selection, 
use, and ongoing surveillance. The paper 
begins with a historical perspective about 
the evaluation of AI in healthcare. It then 
examines key challenges of evaluating 
AI-enabled clinical decision-support. 
The final section deals with the practi-
cal aspects of evaluating AI, including 
approaches to evaluation and indicators 
to monitor AI. It will show that evaluation 
and ongoing surveillance is central to safe 
and effective integration of AI in complex 
sociotechnical settings.
2   Evaluation of AI in 
Healthcare – a Historical 
Perspective 
AI in healthcare is not new, and neither is AI 
evaluation; the dedicated journal, Artificial 
Intelligence in Medicine dates back to the 
early 1990’s. AI as a term was used for a 
collection of established technologies that 
were called decision support technologies, 
knowledge-based systems, or expert sys-
tems in earlier years. The health informatics 
community has a rich history and tradition 
of studying and evaluating the application of 
AI to solve problems in care delivery. Early 
applications were focussed on performing 
diagnosis and making therapy recommenda-
tions in medical settings. The early versions 
of AI mostly used symbolic approaches 
based on rules and knowledge, whereas 
present day AI uses statistical methods 
along with symbolic approaches to disease 
representation. In the late 1950’s, McCar-
thy and colleagues developed the language 
LISP which was particularly well suited to 
symbolic approaches [11]. The PROLOG 
language for logic programming to manage 
reasoning and decision-making processes 
with logical structures was developed in the 
1960’s [12]. In the 1970’s, there was a big 
wave of the so called first generation of AI 
in medicine [13], such as Shortliffe’s work 
with MYCIN [14], Kulikowski’s individu-
alized clinical decision models [15], and de 
Dombal’s computer-aided diagnosis of acute 
abdominal pain [16] which incorporated 
newer statistical reasoning methods such as 
probabilistic reasoning and neural networks. 
Within the period covered above, there 
were extensive discussions about the role of 
AI in medicine, ranging from expert systems 
replacing doctors, to AI supporting doctors 
in their clinical decision-making processes, 
and AI embedded in medical devices. The 
latter has been successfully applied for sev-
eral decades, e.g. in ECG machines and ICU 
equipment such as pumps, and insulin pens.
The need for rigorous evaluation of the 
quality and impact of AI was recognised 
in the 1980s. While the first publications 
focussed mainly on methodologies for 
evaluating performance in a laboratory envi-
ronment, later papers addressed field-testing 
in clinical settings to examine effects on the 
structure, process, and outcome of care deliv-
ery [17-21]. The 1998 Helsinki workshop of 
our IMIA Working Group (then called the 
WG on Technology Assessment and Qual-
ity Development, and Organizational and 
Social Issues) focussed on the importance of 
addressing broader organisational issues and 
the need to focus on constructive evaluation 
within the whole lifecycle of information 
technology (IT) development [22-24]. Two 
books from 2006 which serve as textbooks 
for health IT evaluation methodologies spe-
cifically address techniques for AI as well 
as potential biases that may compromise 
an evaluation [25, 26]. Biases introduced 
during the development of algorithms due to 
differences between training and real-world 
populations are particularly important for 
machine learning-based systems and are 
discussed in section 3.
Later, following implementations of AI 
in clinical practice, studies shifted to the 
clinical impacts of AI [18] and on the related 
methodological challenges to find adequate 
clinical endpoints [19]. Building upon evi-
dence about the benefit of AI in medicine, 
research then focussed on reviewing the 
impact of AI on patient outcomes in inpa-
tient settings [20], in psychiatry [21], and 
medication safety [22].
The challenges recognised in the early 
days of applying AI were among others: 1) 
the legal (e.g., who is responsible when the 
system makes an error?) and ethical issues 
(algorithms dealing with discriminative 
investigations that are highly unethical, see 
for example [27]); 2) the context including 
informal information that is not documented 
in the medical record but is nevertheless 
part of a doctor’s mental image about the 
patient [28]; 3) the transferability of algo-
rithms from one setting to another both with 
respect to patient groups and clinical setting 
(i.e. local technologies/methodologies, local 
or regional professional culture [29]); 4) 
brittleness (inability of AI to reason at the 
boundaries or outside own application range, 
resulting in “sense in – garbage out” [30]; 
and 5) the dynamic nature of professional 
knowledge development in health care that 
needs to be captured in dynamic AI. 
Today, there is an increasing and renewed 
interest in using AI, where a new generation 
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of clinical decision support is facilitated 
by the availability of powerful computing 
tools to manage big data and to analyse and 
generate new knowledge. Big data offers a 
challenge to connect molecular and cellular 
biology to the clinical world and to consider 
individual variations, as well as large volume 
responses and outcomes to similar present-
ing problems, rather than using population 
averages [31] or the restricted population of 
clinical trials. While such advances in tech-
nology may provide solutions to the problem 
of generalisation, they cannot solve all the 
other issues mentioned above. AI now incor-
porates a diverse range of computational 
reasoning methods to support clinicians in 
making decisions. Evaluation of these kinds 
of applications is even more critical as they 
start to penetrate healthcare on a product 
purchase or turn-key basis, where they may 
have an impact on the individual treatment 
of patients and care delivery, as well as on 
the liability of the individual healthcare 
professional. There are also risks related to 
these systems, they may be ill-functioning 
or may even have negative impacts on the 
outcome of care in a specialised unit or a 
different populations or health systems [32]. 
We look at some of these challenges in the 
next section. 
3   Challenges in Evaluating AI 
for Clinical Decision Support
As with all interventions in healthcare we 
need to understand and evaluate the effects 
of AI on care delivery and patient out-
comes. Evaluation is needed at each distinct 
stage in the IT lifecycle including design, 
development, selection, use, and ongoing 
surveillance. 
Design and development of AI: Histori-
cally, evaluation of AI was limited to the 
design and development phase, as imple-
mentation and use of AI systems in routine 
clinical practice was rare. During design and 
development, evaluation concentrates upon 
the performance of the algorithms in terms 
of discrimination, accuracy, and precision. 
Depending on the use case, one performance 
measure might be more important than the 
other. For example, an algorithm used for 
triage needs high discrimination, while an 
algorithm that predicts mortality or compli-
cation risks in shared decision-making needs 
to be highly accurate and precise for all types 
of patients. Even at this stage of performance 
evaluation, we need to recognise that the 
algorithm may be “mathematically optimal 
but ethically problematic” [33]. A fundamen-
tal challenge is that AIs built using machine 
learning do not necessarily generalise 
well beyond the data upon which they are 
trained. Even in restricted tasks like image 
interpretation, AI can make erroneous diag-
noses because of differences in the training 
and real-world populations, including new 
‘edge’ cases, as well as differences in image 
capture workflows [4]. Another challenge 
is that algorithms need to reflect up-to-date 
knowledge given the dynamic changes of 
professional knowledge. Based on which 
knowledge do the algorithms work? What 
level of evidence is sufficient? How is regular 
adaptation to new professional knowledge 
organized? 
Designers also need to consider if the 
computational finding is actionable in an 
ethical way or if it might disadvantage peo-
ple from a particular socio-demographic 
background. For example, an algorithm to 
prioritise which patient should receive an 
organ donated for transplant might include 
expected longevity as a predictor variable. 
This might seem sensible on face value, but 
would ignore the implicit correlation with 
social determinants of health and lifespan 
[33]. Furthermore, the inferential logic 
should be put in context – is the reasoning 
behind the algorithm meaningful in the real 
world or only a statistical artefact? This 
question has been raised about the so-called 
“week-end effect” of apparent increases in 
hospital mortality [34]. Many studies have 
relied upon administrative data to investi-
gate the association between time or day 
of admission and hospital mortality, which 
has resulted in inadequate adjustment for 
case mix difference between weekdays and 
weekends and consequently has produced 
inconsistent findings and conclusions.
Evaluation challenges also arise from the 
nature of AI and the manner in which it is 
developed. Some computational reasoning 
methods in AI such as neural networks 
are considered black boxes to end-users. 
Auditing has been proposed as a pragmatic 
approach to evaluating opaque algorithms 
that were devised autonomously. This 
follows an analogy to human judgement; 
typically we measure outcomes, not prob-
lem-solving style or cognitive process [35]. 
However, given the fundamental healthcare 
ethic of “first do no harm”, we suggest 
more effort is needed in the design phases 
to explain the principles of a computational 
model to allow transparent assessment. This 
would help to keep clinicians and patients 
engaged and avoid conflict between prac-
titioners and commercial algorithm devel-
opers (e.g. [36]). Algorithm developers, 
including those who operate on a proprietary 
basis, need to consider how to open the black 
box (even if partially) and work within a 
framework for shareable biomedical knowl-
edge so that clinicians can judge the merits 
of AI models [37]. 
Selection and use of AI: Widespread 
availability of clinical data, easy to use 
AI development environments (e.g. Ten-
sorflow, DeepLearning4J and Keras [38]) 
and online communities (e.g. healthcare.ai) 
have resulted in rapidly growing numbers 
of algorithms that have become available 
to clinicians. When multiple algorithms 
are available and one must be selected, it is 
important to evaluate any risks of data qual-
ity issues, and poor fit of the foundational 
data to a new situation, such as different 
population and morbidity patterns. What 
does the provenance of an algorithm tell 
us about its generalizability? For example, 
a computation that finds an association 
between blood pressure and complications 
in ICU patients where blood pressure is mea-
sured continuously might not be applicable 
to other hospitalised patients where blood 
pressure is measured perhaps only once 
a day; or between a coronary unit where 
pressure may be controlled in most patients 
and a general surgical ward with a different 
and non-controlled hypertensive population. 
Data generation is often a “social phenom-
enon” [39]: data may flow from unreliable 
processes [40] or human workarounds to 
mandatory entry fields [41]. 
We are also interested in the deci-
sion-making performance of humans with 
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and without AI assistance. Once an algo-
rithm is developed, clinical validation of 
its utility is needed. The algorithm may be 
correct but is it operationally meaningful and 
useful? Does it fit clinical workflow? Does it 
still represent up-to-date clinical knowledge? 
Will it change clinical decisions? What 
level of confidence can be given? A signif-
icant concern here is that when humans are 
assisted by DSSs, they tend to over-rely and 
delegate full responsibility to the DSS rather 
than continuing to be vigilant. This is known 
as automation bias and can have dangerous 
consequences when the DSS is wrong or 
fails, or the presenting problem is subtly 
unique. Previous work has demonstrated the 
effects of automation bias with a prescrib-
ing DSS that was based on simple rules of 
logic [42]. In this study, the presence of the 
DSS reduced the verification of prescription 
safety and increased prescribing errors when 
the DSS was incorrect [43]. With AI, these 
effects of automation bias are likely to be 
exacerbated because of the black box nature 
of many machine learning approaches which 
are not conducive to verification. Methods 
are thus needed to mitigate automation bias, 
for example by improving the interpretability 
of machine learning models, explaining how 
an AI came to a conclusion, and training 
clinicians to maintain vigilance. 
Consideration also needs to be given to the 
various stakeholders involved in processes 
to select AI. Evaluation findings need to be 
communicated in a manner that is under-
standable and meaningful to clinicians, but 
also to administrators and policymakers. One 
possible approach to support better selection 
of AI systems is by labelling. Neither patient 
nor clinician can be fully comfortable in 
the use of AI ‘black box’ decision support 
unless they know the system is appropriately 
created and relevant for their situation. Based 
on the transferability and quality schemas, 
label structures need to be developed which 
identify the training population type includ-
ing demography and treatment setting, the 
nature of the decisions supported, the clinical 
environment, and any problems identified. It 
should be possible to devise a standard popu-
lation characteristics data set that is verifiable, 
yet at the same time does not reveal technical 
design details and thus protects commercial 
confidence. Indeed population information 
may become mandatory as health systems 
are increasingly expecting AI developers to be 
transparent about the limitations and ethical 
examination of the population data used to 
develop algorithms, how data performance 
was validated, and how clinicians integrate 
into care delivery effective treatment and 
value for money [44]. Reporting to trusted 
third parties of any suspected adverse out-
comes would also be valuable. 
Ongoing surveillance of AI: AI will have 
systemic effects in complex sociotech-
nical settings, including aspects such as 
usage, usability, interpretability, up-to-date 
capabilities, safety, unintended effects, 
and ethical issues. Algorithms may affect 
resource allocation and prioritisation, so 
the risk of reinforcing bias in care delivery 
must be considered. Of course, the impact 
of AI on patient outcomes and experience 
and on clinical experience, as well as both 
organisational and social impacts, all need to 
be monitored. Over time, the context, treat-
ment possibilities, and patient population 
might change. Therefore, once implemented, 
ongoing surveillance is needed to monitor 
and recalibrate AI algorithms [45]. This 
surveillance is also needed for dynamic algo-
rithms that continuously update themselves 
based on practice data and published clinical 
evidence. Another aspect is in detecting 
and evaluating “hidden” errors – subtle 
flaws in inferred data or a misconfiguration 
that may not be as obvious as the financial 
“flash crash” of 2010 [46] which may take 
months to be revealed (as with hand-crafted 
algorithms [47]). Thus, evaluation is likely to 
shift from a one-off activity to a continuous 
process to ensure that the use of AI, including 
those incorporating dynamic algorithms, is 
meeting expectations. 
4   Practical Aspects of 
Evaluating AI-enabled 
Clinical Decision Support 
This section examines some of the practical 
aspects of evaluating AI-enabled clinical 
decision support. It begins by consider-
ing broad paradigms and frameworks to 
approach such evaluations. We reviewed 
existing guidelines for conducting and 
reporting evaluation studies, and concluded 
with exemplar indicators to monitor AI. The 
aim is to highlight existing approaches that 
can be readily applied and to identify areas 
where further work is required to meet the 
specific needs of current AI. 
Approaching AI evaluation: As we dis-
cussed in the previous section, evaluating 
AI as a one-off activity will not be sufficient, 
therefore continuous evaluation or surveil-
lance might become necessary to monitor 
the emergent behaviour of AI in complex 
sociotechnical settings, and the response of 
its users. Indeed, it may become an ethical 
imperative as the complexity of interven-
tions and their effects on sociotechnical 
interactions become impossible to predict 
in advance. One paradigm that might be 
particularly relevant for approaching the 
evaluation of AI on an ongoing basis is 
the Learning Healthcare System [48]. 
This paradigm usefully incorporates the 
notion of continuous system improvement 
using locally generated evidence to inform 
practice changes. Such learning can occur 
at different levels including institutional, 
national, or international. While aspects like 
algorithm performance may be addressed at 
institutional level, safety governance might 
be considered at a national level and the 
ethical implications of using AI for clinical 
decision support could be tackled at an 
international level. 
Evaluation guidelines and models: Exist-
ing resources such as the guidelines for Good 
Evaluation Practice in Health Informatics 
(GEP-HI) provide a solid foundation for 
planning and executing evaluation projects 
[49]. Validity of GEP-HI for AI and its 
completeness will become apparent through 
application and use. Similarly, the Statement 
on Reporting of Evaluation Studies in Health 
Informatics (STARE-HI) provides useful 
principles for publication of evaluation stud-
ies [50, 51]. These guidelines support design, 
execution, and reporting of an evaluation 
study irrespective of the type of the system 
under study. The evaluation question and the 
purpose of the study guide the selection of 
evaluation methods and their application. 
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Very important evaluation criteria for AI 
applications include validity of the system, 
i.e. correctness in reasoning, usefulness for 
the clinical practice and effects and impacts 
on clinical work, care processes, and patient 
outcomes. With AI applications that are 
based on big data sets, especially genomic, 
biomarker, and phenotype data from across 
the health system, it is important to ensure 
sufficient coverage, specificity, and validity 
of the data. This will be an additional step 
in the evaluation process with AI systems 
i.e. to assess and collect evidence on data 
quality, and is the key point to prevent unin-
tended consequences and to avoid risks of 
harmful results. 
Understanding of the comparability of 
the design and development situation with 
the potential implementation situation is cru-
cial. Aspects such as the algorithm training 
data set (clinical situation, physiology, and 
demography) are critical, as are treatment 
options and user population (including 
professional and e-health skills). A lot can 
be learned from Implementation science; 
for instance Schloemer and Schröder-Bäck 
have created the useful generic PIET model, 
in which Population, Intervention, (clinical) 
Environment, and Transfer methods are 
decomposed [52]. Adaptation of the sub-cat-
egories of each to fit the AI situation would 
yield a valuable assessment tool. 
Indicators to monitor AI: Implementation 
of AI in an organisation can have an impact 
on several aspects of care quality, depending 
on the clinical area where implemented. 
Existing methodologies for defining indica-
tors for continuous monitoring of health IT 
help not only to pinpoint AI-specific care 
quality indicators, but also to define AI-spe-
cific indicators for AI-quality monitoring and 
surveillance, for example, the methodology 
for the Nordic eHealth Indicators which 
has four major phases including definition 
of the context of measurement, monitoring 
goals (e.g. care quality, efficiency, technol-
ogy quality …etc.), methods for indicator 
selection, and the collection, analysis, and 
feedback of data from relevant user groups 
(Box 1) [53].
Governing AI in healthcare may involve 
trade-offs between risk and rewards. Ques-
tions on ethics, safety, and human values 
at stake depend on the type and purpose of 
use of the technologies, emphasizing the 
importance of the first two phases of the 
methodology. Peer-reviewed literature on 
AI for specific situations remains one solid 
source for practical indicator selection and 
grouping. 
Availability (state of the art) of custom 
AI applications for specific purposes in 
different contexts of use for different user 
groups provides the first level of monitoring, 
important for policy makers for local and 
national steering. If these data are collected 
systematically from a whole country, they 
can also be used as benchmarking data by 
policy makers to steer development and by 
healthcare providers to find best practices 
and learn about different AI solutions. 
The information system (IS) success 
model also offers an option for grouping 
indicators to examine AI quality, focussing 
on system quality, information quality, 
service quality, use, user satisfaction, and 
outcomes [54-56]. Each of these are exam-
ined below: 
System quality: Once implemented, 
AI system requires ongoing surveillance 
based on a set of measures to recalibrate 
AI algorithms. Apart from surveillance tar-
geted directly at AI development, IT System 
quality monitoring includes indicators like 
(IT) accessibility, reliability, flexibility, 
integration, response time, ease of learning 
[55]. Measures and indicators for these are 
targeted at monitoring and development 
of the entire socio-technical system where 
AI is implemented. Function quality is an 
important part of system quality, particularly 
when AI components feed other interim 
processes. AI applications with direct impact 
on patient health can be approached by the 
EU directive for medical devices, including 
the requirements for CE marking with tight 
clinical evidence requirements for Class 
II and III devices according to Regulation 
2017/745 [57]. System quality is directly 
associated with patient safety, and existence 
of CE marking could be one indicator for AI 
quality and a proxy for patient safety. 
Information quality may be the most 
important surveillance and monitoring 
domain for AI algorithms alongside with 
system quality. It covers quality of data 
used as input for the AI as well as quality 
of the output information (e.g. accuracy, 
reliability, relevance, completeness) [55]. 
In addition to these, reproducibility, sensi-
tivity and specificity of the results, type and 
severity of errors, observed versus expected 
error rates, causes of errors, how algorithms 
respond and what indicators to use if input 
data characteristics start vary, and the avail-
ability of data, code, and workflows need 
to be focussed on, since the algorithms are 
Box 1   Defining indicators for monitoring AI.
1 Define context for measurement
1.1 Define AI application
 • Identify AI components and functions within operational system
 • Define outputs (which may be inputs to another component) and risks
1.2 Identify service context and boundaries (on micro-, meso- and macro levels).
1.3 Identify key stakeholders.
2 Define monitoring goals (e.g. safety, usability, transparency, up-to-dateness, 
reliability, patient safety, work process changes).
3 Define methods for indicator selection and categorisation e.g. by reviewing 
expert knowledge, peer-reviewed literature, or existing indicator work.
4 Define data for repeated measurements, analysis, and feedback from 
different user groups 
 • Produce objective reports.
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trained with certain data, and their soundness 
needs to be confirmed in the context of use 
in relation to the quality of actual clinical 
data to be used [58].
Service quality in the IS success model 
refers to help desk-type support available 
for users as well as long-term feedback from 
users for both immediate updates as well as 
for the entire system development. 
System use refers to utilization (e.g. use/
non-use, frequency of use) of the system 
output [55]. AI in healthcare can be used 
for decision support as well as automating 
actions of care (e.g., medication adminis-
tration). Existing OECD and EU eHealth 
monitoring surveys focus on the availability 
and use of HIS [59-61]. Functionalities for 
diagnostic or treatment support (for pro-
fessionals or patients) are not covered in 
the current surveys, and need revisions to 
encompass AI-enabled functionalities.
User satisfaction/acceptance refers to 
user perceptions about system output [55].
Validated satisfaction scales miss indicators 
for trust and competence of the personnel to 
deal with the decisions made by AI (e.g. to 
identify false results, and to record override 
and its contemporaneous justification). The 
competence of professionals to use com-
monly agreed documentation standards, 
structures, and classifications may also 
be essential, since it impacts the quality 
of documentation (input for AI). From 
the viewpoint of patients, barriers to use, 
including trust and difficult instructions are 
likely to become increasingly important with 
growing numbers of AI implementations and 
wider settings. User competence to evaluate 
decisions offered by AI would gain crucial 
importance in future.
Outcomes refer to the individual and 
organizational impacts [55]. AI promises to 
enhance healthcare effectiveness and effi-
ciency, but requires due diligence to validate 
actions, optimise their use, and minimize 
risks. Outcome indicators need to reflect the 
purpose of the algorithm, and can include 
appropriateness of AI-assisted decisions, 
efficiency in care process, as well as patient 
acceptance and adherence. Patient outcomes 
are increasingly important to monitor along 
with patient safety incidents. Monitoring 
risks/adverse effects/trade-offs is an essential 
part of monitoring AI outcomes, including 
equity and inclusion, data privacy and secu-
rity, algorithmic bias, and representativeness 
of data [62].
A broader outlook is also essential, 
rather than solely focussing on the quality 
of algorithms or quality of their outcomes. 
The presence of governance structures 
(e.g. transparency of processes and policies 
to ensure reproducibility for large scale 
computational models, regulation related 
to safe and secure use of data, liability and 
accountability questions, data ownership), 
education and training, as well as national 
development and validation procedures can 
be used as indicators of system maturity on 
national level. 
5   Conclusions 
Technological developments are outpacing 
our ability to predict the effects of AI on 
the practice of medicine, the care received 
by patients, and the impact on their life. 
In the immediate future, we can expect AI 
to support clinical decisions with humans 
in the decision loop. The dynamics of 
decision-making processes are likely to be 
altered with clinicians needing to weigh 
AI-generated advice against other evidence 
and patient preferences [1]. To ensure the 
safe and effective integration of AI in care 
delivery, a robust commitment to evaluation 
is critical. Evaluators can draw important 
lessons from past efforts and should build 
upon current best practice frameworks, 
evaluation guidelines, and methods to guide 
evidence-based design, development, selec-
tion, use, and ongoing surveillance of AI 
in clinical decision support. Labels will be 
important for defining source-training data 
so as to identify optimal transferable use 
patterns. Specific enhancements required 
for evaluating dynamic algorithms incorpo-
rating vast amounts of genomic, biomarker, 
and phenotype data will emerge through 
practical application.
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